#USA #New York #ASCO #Canopy #Remote Therapeutic Monitoring

Canopy's Innovative Approach to Oncology Care at ASCO 2026

On May 21, 2026, Canopy, recognized as a leader in Enterprise AI for oncology, revealed that two of its notable studies were selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is set to take place from May 31 to June 1, 2026. These studies center around the effectiveness of Canopy’s Remote Therapeutic Monitoring (RTM) platform in enhancing patient outcomes through improved therapy management.

Improving Patient Care Outcomes

The first study, titled Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors, has been scheduled for an oral presentation on Sunday, May 31, 2026, from 9:24 AM to 9:36 AM CDT. This groundbreaking research involved 1,549 patients dealing with metastatic solid tumors, showcasing impressive outcomes for those utilizing the Canopy RTM platform:

• - Reduction in Hospitalizations: The study recorded a 28% decrease in hospitalizations among patients using Canopy’s RTM services, translating to a statistically significant risk difference of −3.63 percentage points (p=0.032).
• - Cost Savings: The financial implications were equally noteworthy, with an estimated annualized acute-care cost saving of approximately $3.1 million for every 1,000 patients treated annually.
• - Focus on High-Risk Patients: The research highlighted that the most substantial benefits were witnessed in patients identified as highest-risk, who experienced a remarkable hospitalization reduction of nearly 9 percentage points, deeming the platform essential for those needing critical support during outpatient therapy.

Dr. James Essell, an advisor at Cincinnati Cancer Advisors and the presenting author, noted, "These findings add to the growing evidence supporting remote therapeutic monitoring in outpatient cancer care. For high-risk patients undergoing systemic therapy, the Canopy RTM platform can significantly lower hospitalization rates and lessen acute care costs."

A Deeper Dive into Immune-Checkpoint Inhibitors

The second study, featured as a poster presentation on June 1, 2026, is titled Impact of remote therapeutic monitoring on time to discontinuation and acute care events among patients treated with immune checkpoint inhibitors. This investigation evaluated 1,598 patients undergoing immune-checkpoint inhibitor therapy while using the Canopy RTM platform. Key findings included:

• - Heightened Detection of Symptoms: The ongoing monitoring enabled a marked increase in the identification of crucial immune-related symptoms such as rash, diarrhea, and respiratory issues.
• - Outpatient Steroid Utilization: Patients using the platform saw a significant rise in outpatient steroid usage, estimated at 64% more than patients not using RTM, highlighting the platform's role in better management of treatment side effects.
• - Delayed Treatment Discontinuation: The median time to treatment discontinuation extended to 224 days for patients utilizing Canopy RTM, compared to only 125 days for non-users, a positive indication of better treatment persistence.
• - Hospitalization Rates: The study also noted a 51% reduction in reported hospitalization rates at the 12-month mark (Relative Risk 0.49; p=0.011), underscoring the platform's overall efficacy in reducing acute care needs.
• - Financial Benefits: The economic analysis showed potential annualized acute-care cost savings of about $12.6 million for each 1,000 patients treated yearly.

Dr. Benjamin Derman, an assistant professor at the University of Chicago Medicine and lead author, expressed, "The raised detection rates of potential immune-related symptoms are particularly illuminating. The positive correlation between higher outpatient steroid usage, increased treatment duration, and decreased hospitalizations represents a substantial advancement in outpatient management strategies tailored for immune-related side effects during therapy."

Conclusion

These presentations demonstrate Canopy's commitment to improving oncology patient care through innovative technology and data-driven solutions. Previous studies have already established significant reductions in emergency room visits (22%) and hospitalizations (also 22%) as well as increased treatment adherence (22%-45%) among patients engaged with the Canopy RTM platform. As Canopy continues to expand its influence with over 500 sites of care nationwide, it stands poised to transform oncology practices and patient experiences.

About Canopy: Canopy's mission revolves around harnessing AI technology to facilitate seamless care between patient visits and across various services. For more information, please visit www.canopycare.us.